Parkinson's Disease Evidence Brief
- Jun 26
- 2 min read
40% Gone Before Diagnosis. The Parkinson's detection gap that's costing patients, trials, and time.
By the time someone gets diagnosed with Parkinson's, roughly 40% of their brain's dopamine is already gone.
That's not a typo.
We're not catching this disease early enough. We're catching it late. And that changes everything about how we treat it, how we study it, and whether new therapies actually work.
The numbers are stark:
35-45% of striatal dopamine is lost before diagnosis
60%+ of dopaminergic neurons are damaged before motor symptoms appear
40% of Parkinson's patients never see a neurologist
11.7 million people living with PD globally (and counting)
Here's where it gets worse.
Most Parkinson's research happens through specialty centers and academic medical networks. The people who end up in those studies tend to be those with stable insurance, access to transportation, and the luxury of making frequent visits to specialists. That's a narrow slice of the population.
The people who don't fit that profile - rural patients, low-income families, communities of color, folks with fragmented healthcare access - they're often invisible to clinical research entirely.
And yet, they're the ones who stand to benefit most from earlier detection.
A 2025 study found that Black and Hispanic/Latinx patients with Parkinson's are significantly less likely to receive a timely diagnosis. They're also less likely to receive advanced therapies like deep-brain stimulation. By the time they're diagnosed, symptoms are more advanced. Treatment options are narrower. Research participation windows have closed.
This creates a cycle: reduced access to specialty care leads to reduced research participation, which leads to reduced representation in evidence, which means future treatments are less likely to work for the populations that need them most.
The pipeline of disease-modifying therapies is expanding. But if we're testing them on patients who are already too far gone, and on populations that don't resemble the people who will actually receive those therapies, we're asking the wrong question.
The evidence gap isn't just about when we find Parkinson's. It's about who we're finding, and who we're missing.
We wrote a full evidence brief on how earlier detection, better representation, and smarter recruitment could change the trajectory of Parkinson's research. It covers the data on prodromal signals, the recruitment bottleneck, the equity gap, and what the next five years of evidence generation might look like.
It's not optimistic. It's honest.
